Prevention and treatment of bone metastases

Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.

(2017) M. Gnant et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

(2011) C. Parker et al.   EUROPEAN JOURNAL OF CANCER

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial

(2011) Michael Gnant et al.   LANCET ONCOLOGY

Breast-Cancer Adjuvant Therapy with Zoledronic Acid

(2011) Robert E. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE